Heba Edrees1, Mary G Amato1,2, Adrian Wong1,2, Diane L Seger2,3, David W Bates2,3,4. 1. Department of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences, Boston, Massachusetts, USA. 2. Center for Patient Safety Research and Practice, Division of General Internal Medicine and Primary Care; Brigham and Women's Hospital, Boston, Massachusetts, USA. 3. Clinical and Quality Analysis, Information Systems, Partners HealthCare, Somerville, Massachusetts, USA. 4. Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Abstract
OBJECTIVE: The study sought to determine frequency and appropriateness of overrides of high-priority drug-drug interaction (DDI) alerts and whether adverse drug events (ADEs) were associated with overrides in a newly implemented electronic health record. MATERIALS AND METHODS: We conducted a retrospective study of overridden high-priority DDI alerts occurring from April 1, 2016, to March 31, 2017, from inpatient and outpatient settings at an academic health center. We studied highest-severity DDIs that were previously designated as "hard stops" and additional high-priority DDIs identified from clinical experience and literature review. All highest-severity alert overrides (n = 193) plus a stratified random sample of additional overrides (n = 371) were evaluated for override appropriateness, using predetermined criteria. Charts were reviewed to identify ADEs for overrides that resulted in medication administration. A chi-square test was used to compare ADE rate by override appropriateness. RESULTS: Of 16 011 alerts presented to providers, 15 318 (95.7%) were overridden, including 193 (87.3%) of the highest-severity DDIs and 15 125 (95.8%) of additional DDIs. Override appropriateness was 45.4% overall, 0.5% for highest-severity DDIs and 68.7% for additional DDIs. For alerts that resulted in medication administration (n = 423, 75.0%), 29 ADEs were identified (6.9%, 5.1 per 100 overrides). The rate of ADEs was higher with inappropriate vs appropriate overrides (9.4% vs 4.3%; P = .038). CONCLUSIONS: The override rate was nearly 90% for even the highest-severity DDI alerts, indicating that stronger suggestions should be made for these alerts, while other alerts should be evaluated for potential suppression.
OBJECTIVE: The study sought to determine frequency and appropriateness of overrides of high-priority drug-drug interaction (DDI) alerts and whether adverse drug events (ADEs) were associated with overrides in a newly implemented electronic health record. MATERIALS AND METHODS: We conducted a retrospective study of overridden high-priority DDI alerts occurring from April 1, 2016, to March 31, 2017, from inpatient and outpatient settings at an academic health center. We studied highest-severity DDIs that were previously designated as "hard stops" and additional high-priority DDIs identified from clinical experience and literature review. All highest-severity alert overrides (n = 193) plus a stratified random sample of additional overrides (n = 371) were evaluated for override appropriateness, using predetermined criteria. Charts were reviewed to identify ADEs for overrides that resulted in medication administration. A chi-square test was used to compare ADE rate by override appropriateness. RESULTS: Of 16 011 alerts presented to providers, 15 318 (95.7%) were overridden, including 193 (87.3%) of the highest-severity DDIs and 15 125 (95.8%) of additional DDIs. Override appropriateness was 45.4% overall, 0.5% for highest-severity DDIs and 68.7% for additional DDIs. For alerts that resulted in medication administration (n = 423, 75.0%), 29 ADEs were identified (6.9%, 5.1 per 100 overrides). The rate of ADEs was higher with inappropriate vs appropriate overrides (9.4% vs 4.3%; P = .038). CONCLUSIONS: The override rate was nearly 90% for even the highest-severity DDI alerts, indicating that stronger suggestions should be made for these alerts, while other alerts should be evaluated for potential suppression.
Authors: A Marengoni; L Pasina; C Concoreggi; G Martini; F Brognoli; A Nobili; G Onder; D Bettoni Journal: Eur J Intern Med Date: 2014-10-11 Impact factor: 4.487
Authors: Habibollah Pirnejad; Parasto Amiri; Zahra Niazkhani; Afshin Shiva; Khadijeh Makhdoomi; Saeed Abkhiz; Heleen van der Sijs; Roland Bal Journal: Int J Med Inform Date: 2019-04-13 Impact factor: 4.046
Authors: Adam Wright; Skye Aaron; Diane L Seger; Lipika Samal; Gordon D Schiff; David W Bates Journal: J Gen Intern Med Date: 2018-05-15 Impact factor: 5.128
Authors: T Bakker; J E Klopotowska; S Eslami; D W de Lange; R van Marum; H van der Sijs; E de Jonge; D A Dongelmans; N F de Keizer; A Abu-Hanna Journal: BMC Med Inform Decis Mak Date: 2019-08-13 Impact factor: 2.796
Authors: Teryl K Nuckols; Crystal Smith-Spangler; Sally C Morton; Steven M Asch; Vaspaan M Patel; Laura J Anderson; Emily L Deichsel; Paul G Shekelle Journal: Syst Rev Date: 2014-06-04
Authors: Dustin S McEvoy; Dean F Sittig; Thu-Trang Hickman; Skye Aaron; Angela Ai; Mary Amato; David W Bauer; Gregory M Fraser; Jeremy Harper; Angela Kennemer; Michael A Krall; Christoph U Lehmann; Sameer Malhotra; Daniel R Murphy; Brandi O'Kelley; Lipika Samal; Richard Schreiber; Hardeep Singh; Eric J Thomas; Carl V Vartian; Jennifer Westmorland; Allison B McCoy; Adam Wright Journal: J Am Med Inform Assoc Date: 2017-03-01 Impact factor: 4.497
Authors: Thomas Reese; Adam Wright; Siru Liu; Richard Boyce; Andrew Romero; Guilherme Del Fiol; Kensaku Kawamoto; Daniel Malone Journal: Am J Health Syst Pharm Date: 2022-06-23 Impact factor: 2.980
Authors: Yu Chuan Jack Li; David Westfall Bates; Yen Po Harvey Chin; Wenyu Song; Chia En Lien; Chang Ho Yoon; Wei-Chen Wang; Jennifer Liu; Phung Anh Nguyen; Yi Ting Feng; Li Zhou Journal: JMIR Med Inform Date: 2021-01-27
Authors: Eric Chou; Richard D Boyce; Baran Balkan; Vignesh Subbian; Andrew Romero; Philip D Hansten; John R Horn; Sheila Gephart; Daniel C Malone Journal: JAMIA Open Date: 2021-03-19
Authors: Greet Van De Sijpe; Charlotte Quintens; Karolien Walgraeve; Eva Van Laer; Jens Penny; Greet De Vlieger; Rik Schrijvers; Paul De Munter; Veerle Foulon; Minne Casteels; Lorenz Van der Linden; Isabel Spriet Journal: BMC Med Inform Decis Mak Date: 2022-02-22 Impact factor: 2.796
Authors: Pamela M Garabedian; Michael P Gannon; Skye Aaron; Edward Wu; Zoe Burns; Lipika Samal Journal: BMC Med Inform Decis Mak Date: 2022-08-13 Impact factor: 3.298
Authors: Henry Han; Grace Chung; Emily Sippola; Wilson Chen; Spencer Morgan; Elizabeth Renner; Allison Ruff; Anne Sales; Jacob Kurlander; Geoffrey D Barnes Journal: Res Pract Thromb Haemost Date: 2021-07-16